ATE211737T1 - Tricyclisch substituierte 2,4-dithi(oxo)- pyrimidin-5-yl-verbindungen als p2- purinoceptor- antagonisten - Google Patents
Tricyclisch substituierte 2,4-dithi(oxo)- pyrimidin-5-yl-verbindungen als p2- purinoceptor- antagonistenInfo
- Publication number
- ATE211737T1 ATE211737T1 AT98934002T AT98934002T ATE211737T1 AT E211737 T1 ATE211737 T1 AT E211737T1 AT 98934002 T AT98934002 T AT 98934002T AT 98934002 T AT98934002 T AT 98934002T AT E211737 T1 ATE211737 T1 AT E211737T1
- Authority
- AT
- Austria
- Prior art keywords
- pct
- compounds
- dithi
- pyrimidine
- oxo
- Prior art date
Links
- 239000000423 purinergic P2 receptor antagonist Substances 0.000 title 1
- 229940123344 GPR antagonist Drugs 0.000 abstract 1
- 102000007466 Purinergic P2 Receptors Human genes 0.000 abstract 1
- 108010085249 Purinergic P2 Receptors Proteins 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
- C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/557—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms, e.g. orotic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Peptides Or Proteins (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyridine Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE9702651A SE9702651D0 (sv) | 1997-07-09 | 1997-07-09 | Novel compounds |
| PCT/SE1998/001240 WO1999002501A1 (en) | 1997-07-09 | 1998-06-25 | Novel compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE211737T1 true ATE211737T1 (de) | 2002-01-15 |
Family
ID=20407699
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT98934002T ATE211737T1 (de) | 1997-07-09 | 1998-06-25 | Tricyclisch substituierte 2,4-dithi(oxo)- pyrimidin-5-yl-verbindungen als p2- purinoceptor- antagonisten |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US6107297A (de) |
| EP (1) | EP0996617B1 (de) |
| JP (1) | JP2001509506A (de) |
| AT (1) | ATE211737T1 (de) |
| AU (1) | AU8361198A (de) |
| DE (1) | DE69803458T2 (de) |
| DK (1) | DK0996617T3 (de) |
| ES (1) | ES2171300T3 (de) |
| PT (1) | PT996617E (de) |
| SE (1) | SE9702651D0 (de) |
| WO (1) | WO1999002501A1 (de) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999026944A1 (en) * | 1997-11-21 | 1999-06-03 | Astrazeneka Uk Limited | New compounds which are p2-purinoceptor 7-transmembrane (tm) g-protein coupled receptor antagonists |
| HUP0400179A3 (en) * | 2001-06-12 | 2004-10-28 | Neurogen Corp Branford | 2,5-diarylpyrazines, 2,5-diarylpyridines and 2,5-diarylpyrimidines, their use and pharmaceutical compositions containing them |
| AUPS160602A0 (en) | 2002-04-08 | 2002-05-16 | University Of Queensland, The | Therapeutic method |
| US7179481B2 (en) * | 2002-09-19 | 2007-02-20 | Kimberly-Clark Worldwide, Inc. | Vaginal health products |
| AU2002952086A0 (en) * | 2002-10-16 | 2002-11-07 | The University Of Queensland | Treatment of osteoarthritis |
| US7098189B2 (en) * | 2002-12-16 | 2006-08-29 | Kimberly-Clark Worldwide, Inc. | Wound and skin care compositions |
| US7056889B2 (en) | 2002-12-16 | 2006-06-06 | Kimberly-Clark, Worldwide, Inc. | Compounds that bind P2Y2 or P2Y1 receptors |
| WO2005039506A2 (en) * | 2003-10-24 | 2005-05-06 | Exelixis, Inc. | P70s6 kinase modulators and method of use |
| US7485666B2 (en) * | 2004-06-17 | 2009-02-03 | Kimberly-Clark Worldwide, Inc. | Vaginal health products |
| ES2600460T3 (es) | 2005-05-10 | 2017-02-09 | Intermune, Inc. | Derivados de piridona-2-ona como moduladores del sistema de proteína cinasa activada por estrés |
| JP4431099B2 (ja) | 2005-09-06 | 2010-03-10 | 富士通株式会社 | 波長変換方式、光集積素子及び波長変換方法 |
| US20100291533A1 (en) | 2008-01-04 | 2010-11-18 | Soon Ha Kim | Indole and indazole derivatives having a cell-, tissue- and organ-preserving effect |
| CN102099036B (zh) | 2008-06-03 | 2015-05-27 | 英特芒尼公司 | 用于治疗炎性疾患和纤维化疾患的化合物和方法 |
| CN104024241B (zh) * | 2011-08-01 | 2016-01-20 | 大日本住友制药株式会社 | 尿嘧啶衍生物和其用于医学目的的用途 |
| AR092742A1 (es) | 2012-10-02 | 2015-04-29 | Intermune Inc | Piridinonas antifibroticas |
| MX382781B (es) | 2014-04-02 | 2025-03-13 | Intermune Inc | Piridinonas anti-fibroticas. |
| CN104292267A (zh) * | 2014-09-11 | 2015-01-21 | 北京诺泓医药科技有限公司 | 1-羟基-2-(咪唑并[1,2-a]吡啶-3-基)乙烷-1,1-双膦酸的制备方法 |
| EP4514353A1 (de) | 2022-04-29 | 2025-03-05 | Deutsches Krebsforschungszentrum | P2ry2-aktivitätsmodulatoren |
-
1997
- 1997-07-09 SE SE9702651A patent/SE9702651D0/xx unknown
-
1998
- 1998-06-25 PT PT98934002T patent/PT996617E/pt unknown
- 1998-06-25 AU AU83611/98A patent/AU8361198A/en not_active Abandoned
- 1998-06-25 ES ES98934002T patent/ES2171300T3/es not_active Expired - Lifetime
- 1998-06-25 WO PCT/SE1998/001240 patent/WO1999002501A1/en not_active Ceased
- 1998-06-25 EP EP98934002A patent/EP0996617B1/de not_active Expired - Lifetime
- 1998-06-25 JP JP2000502029A patent/JP2001509506A/ja active Pending
- 1998-06-25 DK DK98934002T patent/DK0996617T3/da active
- 1998-06-25 US US09/155,612 patent/US6107297A/en not_active Expired - Fee Related
- 1998-06-25 AT AT98934002T patent/ATE211737T1/de not_active IP Right Cessation
- 1998-06-25 DE DE69803458T patent/DE69803458T2/de not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EP0996617B1 (de) | 2002-01-09 |
| AU8361198A (en) | 1999-02-08 |
| WO1999002501A1 (en) | 1999-01-21 |
| DK0996617T3 (da) | 2002-04-29 |
| SE9702651D0 (sv) | 1997-07-09 |
| DE69803458D1 (de) | 2002-02-28 |
| DE69803458T2 (de) | 2002-09-12 |
| JP2001509506A (ja) | 2001-07-24 |
| EP0996617A1 (de) | 2000-05-03 |
| PT996617E (pt) | 2002-06-28 |
| ES2171300T3 (es) | 2002-09-01 |
| US6107297A (en) | 2000-08-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE211737T1 (de) | Tricyclisch substituierte 2,4-dithi(oxo)- pyrimidin-5-yl-verbindungen als p2- purinoceptor- antagonisten | |
| TR200101155T2 (tr) | 4-Aroil Piperidin CCR-3 Reseptör Antagonistleri III | |
| MY122392A (en) | Adamantane derivatives of use of p2x7 receptor antagonists, a process for their preparation, pharmaceutical compositions containing them and a process for preparing the pharmaceutical compositions | |
| ATE270663T1 (de) | Trizyklische 1-benzylpyrazol-3- carbonsäurederivate als cannabinoidrezeptorantagonisten | |
| TR200101398T2 (tr) | Pirolidin türevleri-CCR-3 reseptörü antagonistleri. | |
| IL140622A0 (en) | Biphenyl sufonamide derivatives, pharmaceutical compositions containing the same and methods for the preparation thereof | |
| DE69532162D1 (de) | Cannabinoid-rezeptor-antagonisten | |
| ATE381560T1 (de) | Neue benzazepine und ähnliche heterocyclische derivate,die als orexin rezeptor antagonisten geeignet sind | |
| AR002268A1 (es) | Antagonistas de vasopresina de benzacepina triciclicos, un procedimiento para su preparacion, una composicion farmaceutica que los contiene y el uso dedichos compuestos para preparar composiciones farmaceuticas. | |
| ES2182309T3 (es) | Composiciones topicas. | |
| SE9702002D0 (sv) | Novel compounds | |
| ATE245632T1 (de) | Benzodiazepin derivate verwendbar als cck- rezeptoren antagonisten | |
| ATE227276T1 (de) | Neue pyrimidinderivate | |
| EP1100497A4 (de) | Heterocyclyl sulphonamid derivate | |
| DE50008020D1 (de) | Substituierte pyrrolidin-2,3,4-trion-derivate wirksam als nmda-rezeptor-antagonisten | |
| NO963331L (no) | 5-Heteroarylindol-derivater som benzodiazepin-reseptorsete-agonister og antagonister | |
| DK1042320T3 (da) | Nye forbindelser, som er P2-purinoceptor-7-transmembran (TM) G-proteinkoblede receptorantagonister | |
| ATE466862T1 (de) | Sigma-2 rezeptoren als biomarkierer der tumorzellenproliferation | |
| BG102229A (en) | Endothelium receptor antagonists | |
| TR199901380A2 (xx) | Di-ya da triazo-spiro$4,5] dekan t�revleri | |
| NO20000654L (no) | 1,3-dioksolo/4.5-H/2.3/Benzodiazepinderivater som AMPA/kainareseptorinhibitorer | |
| ATE168681T1 (de) | 3-phenylureido-1,5-benzodiazepin-dione verwendbar als gastrin- oder cck antagonisten |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification | ||
| REN | Ceased due to non-payment of the annual fee |